Tirzepatide 'overdose' on TikTok: what actually happened?

What did @amberlykins actually say?

She's been dosing tirzepatide incorrectly for nine weeks and only just figured it out. In her words, she "did it wrong for nine weeks" and "just did my tenth shot correctly." The video caption confirms she was taking more than intended, referencing 25 units (2.5mg) as the correct dose. On day 66 of her journey, she's filming from what sounds like a bed, nauseated, with a headache so severe it took her 30 minutes to wash her face. She also reports being down 10 pounds, from 159 to 150. Critically, she has a type 1 diabetes hashtag on her video, which adds a layer of clinical complexity that she does not address at all in the transcript.

To be clear about what she's documenting: nine weeks of an unintended higher dose, followed by acute side effects severe enough to miss church and struggle with basic self-care tasks.

Does the science back this up?

Yes, mostly. The side effect profile she's describing is textbook tirzepatide overdose territory, and the research supports that. The SURPASS trial series (Dahl et al., 2022, The Lancet) consistently showed nausea, vomiting, and headache as the most common adverse events, dose-dependent and most severe during dose escalation. What she experienced, severe nausea and a pounding headache that ibuprofen couldn't touch, fits this pattern precisely.

The weight loss she reports, 10 pounds over roughly 9 weeks, is plausible but on the modest end compared to trial data. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average losses of 15-20% body weight over 72 weeks at therapeutic doses. At a starting weight of 159 pounds, losing 10 pounds in roughly 9 weeks is real but not exceptional. The complicating factor no one in the comments is probably saying: if she was accidentally overdosing for nine weeks, some of that weight loss may have come from nausea-driven caloric restriction, not the drug's metabolic mechanism alone.

What did they get wrong (or right)?

She got the acknowledgment right. Admitting on camera that you've been dosing a prescription medication incorrectly for over two months takes some courage, and it's genuinely useful for other people who might be making the same mistake with unit-to-milligram conversions on insulin syringes, which is a known and documented source of tirzepatide dosing errors with compounded versions.

What she got wrong, or at minimum dangerously incomplete: she has a type 1 diabetes hashtag on this video and says nothing about it in her narration. Tirzepatide is not approved for type 1 diabetes. The FDA label explicitly excludes it from this population, and there are real concerns about hypoglycemia risk in type 1 patients using GLP-1 receptor agonists alongside insulin (Mathieu et al., 2021, Diabetes Care). Framing an overdose recovery as "good news, I'm 100% better" without addressing any of that is a meaningful omission for a video that 93,000 people have watched.

Taking ibuprofen for a headache while nauseated and likely dehydrated is also not ideal, since NSAIDs can worsen GI distress, but she's not presenting herself as medical advice, to be fair.

What should you actually know?

Dosing errors with compounded tirzepatide are a real and underreported problem. Because compounded versions are often sold in multi-dose vials measured in milligrams per milliliter, users drawing doses with insulin syringes in units can easily miscalculate. The FDA issued a safety communication in 2024 specifically about this risk with compounded GLP-1 medications, citing reports of accidental overdoses resulting in severe nausea, vomiting, and hypoglycemia.

Her recovery taking about 5 days also tracks. Tirzepatide has a half-life of approximately 5 days (Coskun et al., 2022, Clinical Pharmacokinetics), so one week after an accidental higher dose, you would expect symptoms to substantially resolve as the drug clears.

• Compounded tirzepatide is not the same as Mounjaro or Zepbound. Bioequivalence has not been established.
• Unit-to-milligram conversion errors are the most common source of overdose in at-home GLP-1 use.
• Severe headache and nausea post-injection should prompt a call to your prescriber, not ibuprofen and a TikTok.
• Type 1 diabetes and tirzepatide is a complex combination that requires physician oversight, not hashtags.

Bottom line

This video is a useful real-world account of what a tirzepatide dosing error looks like from the inside. The symptoms are consistent with the literature. The transparency is commendable. But 93,000 viewers are watching someone with type 1 diabetes describe an overdose recovery as essentially a minor inconvenience, and that framing deserves more scrutiny than the comment section is probably giving it. If you are using compounded tirzepatide at home, triple-check your unit-to-milligram conversion with your prescribing provider before every dose change.